Table 1

Summary of the per person lifetime costs* and percentage of cases and non-cases genetically tested for each strategy (ordered by increasing cost of strategy)

Strategy	Total undiscounted costs*	Total discounted costs*	Incremental costs versus no testing strategy*	% who are genetically tested
Strategy	Total undiscounted costs*	Total discounted costs*	Incremental costs versus no testing strategy*	With monogenic diabetes	Without monogenic diabetes
Clinical Prediction Model Testing†	£133 200	£53 600	−£100	92	3
Biomarker Testing	£133 300	£53 600	−£100	92	8
Ad Hoc Testing	£133 500	£53 700	0	6	<1
No Testing	£133 600	£53 700	NA	0	0
All Testing	£133 700	£54 000	£300	92	92

*Rounded to nearest £100.
†Probability thresholds chosen to maximise costs saved versus No Testing are 12.6% for type 1 versus monogenic diabetes and 75.5% for type 2 versus monogenic diabetes.